SynthesisPloS one2016
Prognostic Value of Basic Fibroblast Growth Factor (bFGF) in Lung Cancer: A Systematic Review with Meta-Analysis.
Synthesis in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04182698 (Phase I / II Clinical Study on the Safety and Preliminary Efficacy of Anlotinib Hydrochloride Combined With Platinum-containing Simultaneous Radiotherapy in the Treatment of Locally Advanced Non-small Cell Lung Cancer), which is not on this map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase I / II Clinical Study on the Safety and Preliminary Efficacy of Anlotinib Hydrochloride Combined With Platinum-containing Simultaneous Radiotherapy in the Treatment of Locally Advanced Non-small Cell Lung Cancer
Who cites it
23 citing papers in PubMed, 48 citations in OpenAlex.
- Nanotherapeutic Formulations for the Delivery of Cancer Antiangiogenics.Molecular pharmaceutics · 2025Review
- The interaction of platelet-related factors with tumor cells promotes tumor metastasis.Journal of translational medicine · 2024Review
- The dynamic relationship between inorganic polyphosphate and adenosine triphosphate in human non-small cell lung cancer H1299 cells.FEBS open bio · 2024Article
- Predictors of fibrogenesis in children with JIA: a single-center pilot study.Pediatric rheumatology online journal · 2024Article
- Impaired proliferation and migration of HUVEC and melanoma cells by human anti-FGF2 mAbs derived from a murine hybridoma by guided selection.Bioengineered · 2023Article
- Intelligent prognosis evaluation system for stage I-III resected non-small-cell lung cancer patients on CT images: a multi-center study.EClinicalMedicine · 2023Article
- Review
- Germline Variants in Angiogenesis-Related Genes Contribute to Clinical Outcome in Head and Neck Squamous Cell Carcinoma.Cancers · 2022Article
- Host-Related Factors as Targetable Drivers of Immunotherapy Response in Non-Small Cell Lung Cancer Patients.Frontiers in immunology · 2022Review
- Article
- Reversal of Chemotherapy Resistance to Cisplatin in NSCLC by miRNA-195-5p via Targeting thePharmacogenomics and personalized medicine · 2021Article
- Beyond Conventional: The New Horizon of Anti-Angiogenic microRNAs in Non-Small Cell Lung Cancer Therapy.International journal of molecular sciences · 2020Review
- HDGF enhances VEGF‑dependent angiogenesis and FGF‑2 is a VEGF‑independent angiogenic factor in non‑small cell lung cancer.Oncology reports · 2020Article
- Review
- Elevated Platelet Count Appears to Be Causally Associated with Increased Risk of Lung Cancer: A Mendelian Randomization Analysis.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2019Article
- Up-Regulated FGFR1 Expression as a Mediator of Intrinsic TKI Resistance in EGFR-Mutated NSCLC.Translational oncology · 2019Article
- Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics.Molecular therapy. Nucleic acids · 2019Review
- Clinical significance of high expression of miR-452-5p in lung squamous cell carcinoma.Oncology letters · 2018Article
- Angiogenin negatively regulates the expression of basic fibroblast growth factor (bFGF) and inhibits bFGF promoter activity.International journal of clinical and experimental pathology · 2018Article
- Cellular and Molecular Changes in MNU-Induced Breast Tumours Injected with PF4 or bFGFAsian Pacific journal of cancer prevention : APJCP · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBasic fibroblast growth factor (bFGF) is known to stimulate angiogenesis and thus to influence the proliferation, migration and survival of tumor cells. Many studies examined the relationship between human bFGF overexpression and survival in lung cancer patients, but the results have been mixed. To systematically summarize the clinical prognostic function of bFGF in lung cancer, we performed this systematic review with meta-analysis.
methodStudies were identified by an electronic search of PubMed, EMBASE, China National Knowledge Infrastructure and Wanfang databases, including publications prior to August 2014. Pooled hazard ratios (HR) for overall survival (OS) were aggregated and quantitatively analyzed by meta-analysis.
resultsTwenty-two studies (n = 2154) were evaluated in the meta-analysis. Combined HR suggested that bFGF overexpression had an adverse impact on survival of patients with lung cancer(HR = 1.202,95%CI, 1.022-1.382). Our subgroup analysis revealed that the combined HR evaluating bFGF expression on OS in operable non-small cell lung cancer (NSCLC) was 1.553 (95%CI, 1.120-1.986); the combined HR in small cell lung cancer (SCLC) was 1.667 (95%CI, 1.035-2.299). There was no significant impact of bFGF expression on survival in advanced NSCLC.
conclusionThis meta-analysis showed that bFGF overexpression is a potential indicator of worse prognosis for patients with operable NSCLC and SCLC, but is not associated with outcome in advanced NSCLC. The data suggests that high bFGF expression is highly related to poor prognosis. Nevertheless,more high-quality studies should be performed in order to provide additional evidence for the prognostic value of bFGF in lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.